Open AccessSustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials
Author(s) -
Rashmi B. Halker Singh,
Ernesto Aycardi,
Marcelo E. Bigal,
Pippa S. Loupe,
Mirna McDonald,
David W. Dodick
Publication year - 2018
Publication title -
cephalalgia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.57
H-Index - 125
eISSN - 1468-2982
pISSN - 0333-1024
DOI - 10.1177/0333102418772585
Subject(s) - medicine , placebo , migraine , post hoc analysis , chronic migraine , population , anesthesia , alternative medicine , environmental health , pathology
In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and chronic migraine (CM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom